Amalgamated Bank Sells 7,600 Shares of Edwards Lifesciences Co. (NYSE:EW)

Amalgamated Bank reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 123,121 shares of the medical research company’s stock after selling 7,600 shares during the period. Amalgamated Bank’s holdings in Edwards Lifesciences were worth $11,373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in EW. 9258 Wealth Management LLC boosted its position in Edwards Lifesciences by 24.8% in the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock worth $803,000 after purchasing an additional 2,093 shares during the last quarter. Gryphon Financial Partners LLC raised its stake in shares of Edwards Lifesciences by 35.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock worth $492,000 after purchasing an additional 1,698 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Edwards Lifesciences by 5.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,172,836 shares of the medical research company’s stock worth $89,433,000 after buying an additional 58,442 shares during the last quarter. Great Lakes Advisors LLC grew its position in Edwards Lifesciences by 4.5% during the fourth quarter. Great Lakes Advisors LLC now owns 14,150 shares of the medical research company’s stock valued at $1,079,000 after buying an additional 611 shares during the period. Finally, Coldstream Capital Management Inc. increased its holdings in Edwards Lifesciences by 22.7% during the fourth quarter. Coldstream Capital Management Inc. now owns 7,724 shares of the medical research company’s stock worth $589,000 after buying an additional 1,427 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,101,530.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,250 shares of company stock valued at $1,218,138. 1.29% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have weighed in on EW. UBS Group dropped their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Evercore ISI dropped their price objective on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a research note on Thursday, July 25th. Citigroup raised their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. Truist Financial lowered their target price on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating on the stock in a research note on Friday, September 13th. Finally, Stifel Nicolaus cut their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $79.82.

Edwards Lifesciences Stock Up 0.4 %

EW opened at $67.53 on Thursday. The firm has a market capitalization of $40.69 billion, a P/E ratio of 29.11, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a fifty day moving average price of $70.89 and a 200-day moving average price of $83.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.66 earnings per share. Equities research analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.